Under the terms of the agreement, Kyorin will receive $55m upfront and will be eligible for milestone payments of up to ...

Novartis (NYSE:NVS) to acquire Anthos Therapeutics for a total deal value of up to $3.1B, consisting of an upfront payment of $925M, with potential additional payments of up to $2.15B.

The acquisition of Anthos Therapeutics and strategic investments in R&D confirmed our thesis on Novartis' new pure play as an innovative medicines leader. Novartis' strong FCF generation ...

In this article, we will look at the 11 Best Undervalued Stocks to Invest in Now.

Novartis will buy Anthos Therapeutics, a Boston-based biotech focused on cardiac conditions, for an up front payment of $925 million. Anthos was founded in 2019 by Novartis and the private equity ...

Let's continue. An additional factor that, in my opinion, makes Novartis an attractive stock for long-term investors is its acquisition of Anthos Therapeutics for up to $3.1 billion. I believe ...

Also Read: Novartis To Beef Up Heart Disease Offering With $3 Billion Blackstone-Backed Anthos Therapeutics Deal For over 30 years, Congress has imposed price ceilings on prescription drugs ...

We recently compiled a list of the 11 Best Undervalued Stocks to Invest in Now. In this article, we are going to take a look at where Novartis AG (NYSE:NVS) stands against the other undervalued stocks ...